Innovative Approaches of Cancer Therapy

Yavuz DODURGAa , Mücahit SEÇMEb
aPamukkale University Faculty of Medicine, Department of Medical Biology, Denizli, Türkiye
bOrdu University Faculty of Medicine, Department of Medical Biology, Ordu, Türkiye

Dodurga Y, Seçme M. Innovative approaches of cancer therapy. In: Yar Sağlam AS, ed. Innovative Approaches in Cancer Diagnosis and Treatment. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.1-6.

Makale Dili: EN

ABSTRACT
Cancer is a global public health problem responsible for one in six deaths worldwide and its treatment is complex process. In addition to current treatment approaches such as surgery, chemotherapy and radiotherapy, there have been recent advances in cancer treatment. Several technologies are currently being evaluated in clinical trials or have already been introduced into clinical practice. Current treatment modalities in oncology focus on the development of safe and effective cancer nanomedicine products. Tissue regeneration by stem cell therapy has shown promising efficacy. With the advancement of nanotechnology, targeted studies on the use of nanoparticles in cancer diagnosis and treatment have increased. Scientific research and innovations in treatment strategies such as gene therapy, immunotherapy and ablation therapy have gained momentum. Many new technologies and innovative approaches are being investigated in clinical trials in the field of oncology, offering more effective treatment options.

Keywords: Cancer therapy; nanomedicine; genetic therapy; immunotherapy

Referanslar

  1. Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: current perspectives and new challenges. Ecancermedicalscience. 2019;13:961. [Crossref]  [PubMed]  [PMC]
  2. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81-94. [Crossref]  [PubMed]
  3. Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 2021;9:20503121211034366. [Crossref]  [PubMed]  [PMC]
  4. Roy A, Li SD. Modifying the tumor microenvironment using nanoparticle therapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016; 8(6):891-908. [Crossref]  [PubMed]  [PMC]
  5. Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022-43. [Crossref]  [PubMed]  [PMC]
  6. Abbas Z, Rehman S. An overview of cancer treatment modalities. Neoplasm. 2018;1:139-57. [Crossref]
  7. Arruebo M, Vilaboa N, Sáez-Gutierrez B, Lambea J, Tres A, Valladares M, et al. Assessment of the evolution of cancer treatment therapies. Cancers. 2011;3(3):3279-330. [Crossref]  [PubMed]  [PMC]
  8. Moses MA, Brem H, Langer R. Advancing the field of drug delivery: taking aim at cancer. Cancer Cell. 2003;4(5):337-41. [Crossref]  [PubMed]
  9. Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes & Diseases. 2022;10(4):1367-401. [Crossref]  [PubMed]  [PMC]
  10. El-Readi MZ, Althubiti MA. Cancer nanomedicine: a new era of successful targeted therapy. J Nanomater. 2019;4927312. [Crossref]
  11. Tinkle S, McNeil SE, Mühlebach S, Bawa R, Borchard G, Barenholz YC, et al. Nanomedicines: addressing the scientific and regulatory gap. Annals of the New York Academy of Sciences. 2014;1313:35-56. [Crossref]  [PubMed]
  12. Siafaka PI, Üstündağ Okur N, Karavas E, Bikiaris DN. Surface modified multifunctional and stimuli responsive nanoparticles for drug targeting: current status and uses. Int J Mol Sci. 2016;17:1440 [Crossref]  [PubMed]  [PMC]
  13. He, K, Chen M, Liu J, Du S, Ren C, Zhang, J. Nanomedicine for cancer targeted therapy with autophagy regulation. Frontiers Immunology. 2024;14:1238827. [Crossref]  [PubMed]  [PMC]
  14. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annual Review of Biomedical Engineering. 2012;14:1-16. [Crossref]  [PubMed]
  15. Oryani MA, Nosrati S, Javid H, Mehri A, Hashemzadeh A, Karimi-Shahri M. Targeted cancer treatment using folate-conjugated sponge-like ZIF-8 nanoparticles: a review. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024;397(3):1377-404. [Crossref]  [PubMed]
  16. Fang RH, Gao W, Zhang L. Targeting drugs to tumours using cell membranecoated nanoparticles. Nat Rev Clin Oncol. 2023;20:33-48. [Crossref]  [PubMed]
  17. Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;16014. [Crossref]
  18. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology. 2007;2(12):751-60. [Crossref]  [PubMed]
  19. Matea CT, Mocan T, Tabaran F, Pop T, Mosteanu O, Puia C, et al. Quantum dots in imaging, drug delivery and sensor applications. International journal of nanomedicine. 2017;12:5421-31. [Crossref]  [PubMed]  [PMC]
  20. Gao J, Chen K, Miao Z, Ren G, Chen X, Gambhir SS, et al. Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials. 2011;32(8):2141-8. [Crossref]  [PubMed]  [PMC]
  21. Chellachamy Anbalagan A, Korram J, Doble M, Sawant SN. Bio-functionalized carbon dots for signaling immuno-reaction of carcinoembryonic antigen in an electrochemical biosensor for cancer biomarker detection. Discover nano. 2024;19(1):37. [Crossref]  [PubMed]  [PMC]
  22. Gubernator J. Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity. Expert Opin Drug Deliv. 2011;8(5):565-80. [Crossref]  [PubMed]
  23. Li B, Ashrafizadeh M, Jiao T. Biomedical application of metal-organic frameworks (MOFs) in cancer therapy: Stimuli-responsive and biomimetic nanocomposites in targeted delivery, phototherapy and diagnosis. International Journal of Biological Macromolecules. 2024;260(Pt 2):129391. [Crossref]  [PubMed]
  24. Dang BN, Kwon TK, Lee S, Jeong JH, Yook S. Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy. Journal of controlled release: official journal of the Controlled Release Society. 2024;365:773-800. [Crossref]  [PubMed]
  25. Naji A, Eitoku M, Favier B, Deschaseaux F, Rouas-Freiss N, Suganuma N. Biological functions of mesenchymal stem cells and clinical implications. Cellular and molecular life sciences : CMLS. 2019;76(17):3323-48. [Crossref]  [PubMed]  [PMC]
  26. Zhang J, Yuan Z, Zhong W, Wei Y. Stem Cell as Vehicles of Antibody in Treatment of Lymphoma: a Novel and Potential Targeted Therapy. Stem Cell Reviews and Reports. 2021;17(3):829-41. [Crossref]  [PubMed]
  27. Wang Z, Li R, Yang G, Wang Y. Cancer stem cell biomarkers and related signalling pathways. Journal of Drug Targeting. 2024;32(1):33-44. [Crossref]  [PubMed]
  28. Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L, Wandt H, et al. Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. Journal Clinical Oncology. 2010;28(20):3344-51. [Crossref]  [PubMed]
  29. Batlle E, Clevers H. Cancer stem cells revisited. Nature Medicine. 2017;23(10):1124-34. [Crossref]  [PubMed]
  30. Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochimica et Biophysica Acta. 2012;1820(7):940-8. [Crossref]  [PubMed]
  31. Martinelli C. Exosomes: new biomarkers for targeted cancer therapy Molecular Oncology: Underlying Mechanisms and Translational Advancements. Chapter 6. 1st ed. Switzerland AG: Springer Nature; 2017. p.129-57. [Crossref]
  32. Wang Z, Wang Q, Qin F, Chen J. Exosomes: a promising avenue for cancer diagnosis beyond treatment. Frontiers in Cell and Developmental Biology. 2024;12:1344705. [Crossref]  [PubMed]  [PMC]
  33. Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immu-notherapy: From t cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651-68. [Crossref]  [PubMed]  [PMC]
  34. Lefler DS, Manobianco SA, Bashir B. Immunotherapy resistance in solid tumors: mechanisms and potential solutions. Cancer Biology & Therapy. 2024;25(1):2315655. [Crossref]  [PubMed]  [PMC]
  35. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2001;1(2):118-29. [Crossref]  [PubMed]
  36. Adams GP, and Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23:1147-57. [Crossref]  [PubMed]
  37. Shinohara ET, Lu B, Hallahan DE. The use of gene therapy in cancer research and treatment. Technology in Cancer Research & Treatment. 2004;3(5):479-90. [Crossref]  [PubMed]
  38. Chen L, Waxman DJ. Cytochrome P450 Gene-directed Enzyme Prodrug Therapy (GDEPT) for Cancer. Curr Pharm Des. 2002;8:1405-16. [Crossref]  [PubMed]
  39. Hege KM, Carbone DP. Lung cancer vaccines and gene therapy. Lung cancer (Amsterdam, Netherlands). 2003;41 Suppl 1:S103-13. [Crossref]  [PubMed]
  40. Hersey P, Menzies SW, Halliday GM, Nguyen T, Farrelly ML, DeSilva C, et al. Phase I/II Study of Treatment with Dendritic Cell Vaccines in Patients with Disseminated Melanoma. Cancer Immunol. Immunother. 2004;53:125-34. [Crossref]  [PubMed]  [PMC]
  41. Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, et al. Phase I Study of Intranodal Delivery of a Plasmid DNA Vaccine for Patients with Stage IV Melanoma. Cancer. 2003;9:144-54. [Crossref]  [PubMed]
  42. Pantuck AJ, van Ophoven A, Gitlitz BJ, Tso CL, Acres B, Squiban P, et al. Phase I Trial of Antigen-specific Gene Therapy Using a Recombinant Vaccinia Virus Encoding MUC-1 and IL-2 in MUC-1-positive Patients with Advanced Prostate Cancer. J Immunother. 2004;27:240-53. [Crossref]  [PubMed]
  43. Wang Y, Zhang R, Tang L, Yang L. Nonviral Delivery Systems of mRNA Vaccines for Cancer Gene Therapy. Pharmaceutics. 2022;14(3):512. [Crossref]  [PubMed]  [PMC]